Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis

European Journal of Cancer

Volumn 49, Issue 5, 2013, Pages 1027-1031

  Montemurro, M ^a   Gelderblom, H ^b   Bitz, U ^c   Schutte J ^d   Blay, J Y ^e   Joensuu, H ^f   Trent, J ^g,h   Bauer, S ⁱ   Rutkowski, P ^j   Duffaud, F ^k   Pink, D ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HELIOS Klinikum Bad Saarow   (Germany)

^d MARIEN HOSPITAL DÜSSELDORF   (Germany)

^e CENTRE LÉON BÉRARD   (France)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k TIMONE HOSPITAL   (France)

more..

Author keywords

Gastrointestinal stromal tumour; GIST; Imatinib; Nilotinib; Progression; Relapse; Salvage; Sorafenib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; EVEROLIMUS; IMATINIB; NILOTINIB; PERIFOSINE; SORAFENIB; SUNITINIB; VATALANIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CENTER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EUROPE; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SKIN TOXICITY; UNITED STATES; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874941069     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.10.009     Document Type: Article

References (21)

1. M. Montemurro, and S. Bauer Treatment of gastrointestinal stromal tumor after imatinib and sunitinib Curr Opin Oncol 23 2011 367 372
2. Demetri GD, Le Cesne A, Von Mehren M, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. In: ASCO gastrointestinal cancers symposium 2010, San Francisco, USA; 2010 [Abstract 64].
3. P. Schoffski, P. Reichardt, and J.Y. Blay A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Ann Oncol 21 2010 1990 1998
4. J. Maurel, A.S. Martins, and A. Poveda Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas Cancer 116 2010 3692 3701
5. M. Montemurro, P. Schoffski, and P. Reichardt Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib Eur J Cancer 45 2009 2293 2297
6. P. Reichardt, J. Blay, and H. Gelderblom Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3 ASCO Meet Abstr 28 2010 10017
7. T. Guo, N.P. Agaram, and G.C. Wong Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor Clin Cancer Res 13 2007 4874 4881
8. M.C. Heinrich, R. Carden, and D. Griffith In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors ASCO Meet Abstr 27 2009 10500
9. H. Huynh, J.W. Lee, and P.K. Chow Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor Mol Cancer Ther 8 2009 152 159
10. L. Wiebe, K.E. Kasza, and R.G. Maki Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium J Clin Oncol (Meeting Abstr) 26 2008 10502
11. CTEP. Common Terminology Criteria for Adverse Events (v3.0); 2006.
12. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
13. U.S. Dept. of Health and Human Services FDA C, CBER. Guidance for industry-clinical trial endpoints for the approval of cancer drugs and biologics, ; 2007 [accessed 12.08.2011].
14. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. A.P. Conley, D. Araujo, and J. Ludwig A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) ASCO Meet Abstr 27 2009 10563
16. H. Joensuu, F. De Braud, and G. Grignagni Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study Br J Cancer 104 2011 1686 1690
17. P. Reichardt, M. Montemurro, and H. Gelderblom Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis ASCO Meet Abstr 27 2009 10564
18. H.L. Kindler, N.P. Campbell, and K. Wroblewski Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial ASCO Meet Abstr 29 2011 10009
19. M. Ryu, S.H. Park, and B. Ryoo A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: a KGSG study ASCO Meet Abstr 29 2011 10010
20. M.C. Heinrich, K. Owzar, and C.L. Corless Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 26 2008 5360 5367
21. M.C. Heinrich, R.G. Maki, and C.L. Corless Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor J Clin Oncol 26 2008 5352 5359